Price Action Alert: Does Cara Therapeutics Inc Have Any Gas After Today’s Significant Increase?

Price Action Alert: Does Cara Therapeutics Inc Have Any Gas After Today's Significant Increase?

The stock of Cara Therapeutics Inc (NASDAQ:CARA) is a huge mover today! About 983,640 shares traded hands or 1.00% up from the average. Cara Therapeutics Inc (NASDAQ:CARA) has risen 69.72% since February 29, 2016 and is uptrending. It has outperformed by 57.50% the S&P500.
The move comes after 9 months positive chart setup for the $239.22 million company. It was reported on Oct, 4 by We have $25.77 PT which if reached, will make NASDAQ:CARA worth $476.05 million more.

Analysts await Cara Therapeutics Inc (NASDAQ:CARA) to report earnings on November, 14. They expect $-0.47 EPS, down 147.37% or $0.28 from last year’s $-0.19 per share. After $-0.48 actual EPS reported by Cara Therapeutics Inc for the previous quarter, Wall Street now forecasts -2.08% EPS growth.

Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage

Out of 3 analysts covering Cara Therapeutics (NASDAQ:CARA), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cara Therapeutics has been the topic of 3 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Needham maintained it with “Buy” rating and $27 target price in Friday, July 24 report. Cantor Fitzgerald initiated the shares of CARA in a report on Wednesday, November 4 with “Buy” rating.

According to Zacks Investment Research, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.”

Insitutional Activity: The institutional sentiment decreased to 0.7 in Q2 2016. Its down 0.32, from 1.02 in 2016Q1. The ratio is negative, as 27 funds sold all Cara Therapeutics Inc shares owned while 20 reduced positions. 6 funds bought stakes while 27 increased positions. They now own 13.15 million shares or 19.13% less from 16.26 million shares in 2016Q1.
Tudor Invest Corporation Et Al has invested 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). The Maryland-based Proshare Advsrs Limited Liability Company has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Bridgeway Mngmt holds 131,646 shares or 0.01% of its portfolio. Cam Grp Holdg A S holds 0.02% or 268,000 shares in its portfolio. California Public Employees Retirement Sys holds 0% or 142,500 shares in its portfolio. Franklin Resource Inc accumulated 0% or 611,400 shares. Blackrock Advsrs Limited Co has invested 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). The Massachusetts-based Panagora Asset Mngmt has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Baldwin Brothers Inc Ma holds 0.04% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 39,354 shares. Opaleye Management owns 675,000 shares or 1.77% of their US portfolio. New York State Common Retirement Fund accumulated 19,600 shares or 0% of the stock. Voya Investment Management Ltd Limited Liability Company has 0% invested in the company for 10,670 shares. National Planning accumulated 0.03% or 57,450 shares. Deutsche Financial Bank Ag last reported 12,662 shares in the company. Susquehanna Limited Liability Partnership last reported 22,188 shares in the company.

Insider Transactions: Since April 20, 2016, the stock had 0 insider buys, and 1 insider sale for $54,000 net activity. On Wednesday, April 20 the insider Menzaghi Frederique Ph.D. sold $54,000.

CARA Company Profile

Cara Therapeutics, Inc., incorporated on July 2, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Firm operates through the activities related to the discovery and development of novel therapeutics to treat serious medical conditions, including pain and pruritus segment. The Firm is engaged in developing product candidates that focus on the body’s peripheral nervous system. The Company’s product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment